Research Partnership's new report on living with rheumatoid arthritis (RA) is aimed at "helping pharmaceutical companies understand the attitudes and unmet needs of people with RA and how current market dynamics, with the advent of new biologics/biosimilars and oral JAK inhibitors, have affected patients’ views and behaviours towards their RA". Living with Rheumatoid Arthritis (RA) is based on 431 patients diagnosed with RA in the 5 EU markets (France, Germany, Italy, Spain, UK), 56 patients in Japan, and 112 patients in Canada. The study consists of 30-minute quantitative online and qualitative telephone interviews with patients. Research Partnership's Mariel Metcalfe commented: “An inescapable characteristic of RA is that it is unpredictable and can highly impact patients’ practical and emotional lives. While the range of RA treatments has grown, it is even more important to understand and measure how patients view these treatments and if they are truly meeting their needs.” Living with RA is one in a series of "Living With" reports offering insight into the chronic disease patient journey from pre-diagnosis to stabilization, which include Atopic Dermatitis (EU & US), Psoriasis (EU), NASH (EU & US) and Diabetes LATAM. www.researchpartnership.com/livingwith
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.